CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Boston, Massachusetts, United States and 34 other locations
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and i...
Phase 1, Phase 2
Boston, Massachusetts, United States and 8 other locations
at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...
Phase 1, Phase 2
Boston, Massachusetts, United States and 12 other locations
in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections.All par...
Phase 1, Phase 2
Boston, Massachusetts, United States and 5 other locations
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...
Phase 1
Worcester, Massachusetts, United States and 29 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Boston, Massachusetts, United States and 56 other locations
to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...
Phase 1
Boston, Massachusetts, United States and 17 other locations
intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to...
Phase 1, Phase 2
Boston, Massachusetts, United States and 8 other locations
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non...
Phase 1
Boston, Massachusetts, United States and 5 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Boston, Massachusetts, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal